Logo image of FLGT

FULGENT GENETICS INC (FLGT) Stock Fundamental Analysis

NASDAQ:FLGT - Nasdaq - US3596641098 - Common Stock - Currency: USD

21.04  +0.37 (+1.79%)

Fundamental Rating

4

FLGT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. The financial health of FLGT is average, but there are quite some concerns on its profitability. FLGT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

FLGT had positive earnings in the past year.
In the past year FLGT had a positive cash flow from operations.
In multiple years FLGT reported negative net income over the last 5 years.
FLGT had a positive operating cash flow in each of the past 5 years.
FLGT Yearly Net Income VS EBIT VS OCF VS FCFFLGT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

FLGT's Return On Assets of -3.38% is on the low side compared to the rest of the industry. FLGT is outperformed by 61.76% of its industry peers.
Looking at the Return On Equity, with a value of -3.62%, FLGT is in line with its industry, outperforming 48.04% of the companies in the same industry.
Industry RankSector Rank
ROA -3.38%
ROE -3.62%
ROIC N/A
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
FLGT Yearly ROA, ROE, ROICFLGT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

FLGT's Gross Margin of 38.80% is fine compared to the rest of the industry. FLGT outperforms 67.65% of its industry peers.
FLGT's Gross Margin has declined in the last couple of years.
FLGT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
FLGT Yearly Profit, Operating, Gross MarginsFLGT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

6

2. Health

2.1 Basic Checks

FLGT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FLGT has more shares outstanding
The number of shares outstanding for FLGT has been increased compared to 5 years ago.
The debt/assets ratio for FLGT has been reduced compared to a year ago.
FLGT Yearly Shares OutstandingFLGT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
FLGT Yearly Total Debt VS Total AssetsFLGT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

FLGT has an Altman-Z score of 5.87. This indicates that FLGT is financially healthy and has little risk of bankruptcy at the moment.
FLGT has a Altman-Z score of 5.87. This is amongst the best in the industry. FLGT outperforms 88.24% of its industry peers.
FLGT has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
FLGT has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. FLGT outperforms 86.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.87
ROIC/WACCN/A
WACC9.05%
FLGT Yearly LT Debt VS Equity VS FCFFLGT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 6.32 indicates that FLGT has no problem at all paying its short term obligations.
FLGT has a better Current ratio (6.32) than 95.10% of its industry peers.
A Quick Ratio of 6.32 indicates that FLGT has no problem at all paying its short term obligations.
The Quick ratio of FLGT (6.32) is better than 95.10% of its industry peers.
Industry RankSector Rank
Current Ratio 6.32
Quick Ratio 6.32
FLGT Yearly Current Assets VS Current LiabilitesFLGT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

6

3. Growth

3.1 Past

FLGT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 370.00%, which is quite impressive.
The Earnings Per Share has been growing by 22.18% on average over the past years. This is a very strong growth
FLGT shows a small growth in Revenue. In the last year, the Revenue has grown by 1.69%.
FLGT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 54.21% yearly.
EPS 1Y (TTM)370%
EPS 3Y-68.94%
EPS 5Y22.18%
EPS Q2Q%500%
Revenue 1Y (TTM)1.69%
Revenue growth 3Y-34.15%
Revenue growth 5Y54.21%
Sales Q2Q%13.92%

3.2 Future

The Earnings Per Share is expected to decrease by -41.49% on average over the next years. This is quite bad
FLGT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.88% yearly.
EPS Next Y-217.26%
EPS Next 2Y-81.78%
EPS Next 3Y-41.49%
EPS Next 5YN/A
Revenue Next Year9.64%
Revenue Next 2Y10.04%
Revenue Next 3Y9.88%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
FLGT Yearly Revenue VS EstimatesFLGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
FLGT Yearly EPS VS EstimatesFLGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 10 15

0

4. Valuation

4.1 Price/Earnings Ratio

FLGT is valuated quite expensively with a Price/Earnings ratio of 38.96.
Compared to the rest of the industry, the Price/Earnings ratio of FLGT is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 26.29, FLGT is valued a bit more expensive.
FLGT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 38.96
Fwd PE N/A
FLGT Price Earnings VS Forward Price EarningsFLGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FLGT Per share dataFLGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

FLGT's earnings are expected to decrease with -41.49% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)1.76
EPS Next 2Y-81.78%
EPS Next 3Y-41.49%

0

5. Dividend

5.1 Amount

No dividends for FLGT!.
Industry RankSector Rank
Dividend Yield N/A

FULGENT GENETICS INC

NASDAQ:FLGT (6/3/2025, 10:56:21 AM)

21.04

+0.37 (+1.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-02 2025-05-02/bmo
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners57.12%
Inst Owner Change-3.73%
Ins Owners32.27%
Ins Owner Change6.7%
Market Cap640.46M
Analysts77.78
Price Target23.12 (9.89%)
Short Float %8.73%
Short Ratio3.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)126.5%
Min EPS beat(2)121.2%
Max EPS beat(2)131.8%
EPS beat(4)4
Avg EPS beat(4)175.06%
Min EPS beat(4)121.2%
Max EPS beat(4)298.21%
EPS beat(8)7
Avg EPS beat(8)131.64%
EPS beat(12)11
Avg EPS beat(12)134.14%
EPS beat(16)14
Avg EPS beat(16)104.46%
Revenue beat(2)1
Avg Revenue beat(2)-0.36%
Min Revenue beat(2)-1.8%
Max Revenue beat(2)1.07%
Revenue beat(4)2
Avg Revenue beat(4)-0.46%
Min Revenue beat(4)-1.93%
Max Revenue beat(4)1.07%
Revenue beat(8)5
Avg Revenue beat(8)4.57%
Revenue beat(12)9
Avg Revenue beat(12)5.79%
Revenue beat(16)11
Avg Revenue beat(16)4.72%
PT rev (1m)13.33%
PT rev (3m)-13.92%
EPS NQ rev (1m)0.9%
EPS NQ rev (3m)-5605.41%
EPS NY rev (1m)14.65%
EPS NY rev (3m)-54.34%
Revenue NQ rev (1m)-1.01%
Revenue NQ rev (3m)-7.16%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)-5.48%
Valuation
Industry RankSector Rank
PE 38.96
Fwd PE N/A
P/S 2.19
P/FCF N/A
P/OCF 68.4
P/B 0.57
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)0.54
EY2.57%
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)0.31
OCFY1.46%
SpS9.61
BVpS37.03
TBVpS31.94
PEG (NY)N/A
PEG (5Y)1.76
Profitability
Industry RankSector Rank
ROA -3.38%
ROE -3.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.8%
FCFM N/A
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
F-Score7
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 169.44%
Cap/Sales 14.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.32
Quick Ratio 6.32
Altman-Z 5.87
F-Score7
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)101.39%
Cap/Depr(5y)338.11%
Cap/Sales(3y)8.31%
Cap/Sales(5y)7.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)370%
EPS 3Y-68.94%
EPS 5Y22.18%
EPS Q2Q%500%
EPS Next Y-217.26%
EPS Next 2Y-81.78%
EPS Next 3Y-41.49%
EPS Next 5YN/A
Revenue 1Y (TTM)1.69%
Revenue growth 3Y-34.15%
Revenue growth 5Y54.21%
Sales Q2Q%13.92%
Revenue Next Year9.64%
Revenue Next 2Y10.04%
Revenue Next 3Y9.88%
Revenue Next 5YN/A
EBIT growth 1Y0.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year57.6%
EBIT Next 3Y25.69%
EBIT Next 5YN/A
FCF growth 1Y-175.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.63%
OCF growth 3Y-66.06%
OCF growth 5Y30.8%